Affiliation: Harvard University
- Audiology in the sudden hearing loss clinical trialChris Halpin
Department of Audiology, Massachusetts Eye and Ear Infirmary, USA
Otol Neurotol 33:907-11. 2012..To report the pretreatment and posttreatment population characteristics and the overall stability of the audiologic outcomes found during the Sudden Hearing Loss Clinical Trial (ClinicalTrials.gov: Identifier NCT00097448)...
- Improvement in word recognition score with level is associated with hearing aid ownership among patients with hearing lossChris Halpin
Department of Audiology, Massachusetts Eye and Ear Infirmary, Boston, USA
Audiol Neurootol 17:139-47. 2012....
- Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannomaScott R Plotkin
Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA
J Neurooncol 93:61-77. 2009..We encourage adoption of standardized endpoints early in the development of phase II trials for this population to facilitate comparison of results across trials of different agents...
- Hearing aids and cochlear damage: the case against fitting the pure tone audiogramChris Halpin
Department of Audiology, Massachusetts Eye and Ear Infirmary, Boston, MA, USA
Otolaryngol Head Neck Surg 140:629-32. 2009..We recommend that it is better to accommodate the damaged cochlea in these cases than to attempt to reverse-engineer the audiometric test results...
- Clinical implications of a damaged cochlea: pure tone thresholds vs information-carrying capacityChris Halpin
Department of Audiology, Massachusetts Eye and Ear Infirmary, Boston, MA 02114, USA
Otolaryngol Head Neck Surg 140:473-6. 2009..We argue that word recognition testing at low vs high presentation levels provides a quantification of the cochlea's information-carrying capacity and is a useful predictor of word recognition limits with hearing aids...
- Hearing and facial function outcomes for neurofibromatosis 2 clinical trialsScott R Plotkin
From the Neurology Department and Cancer Center S R P and Neurosurgical Service F G B, Massachusetts General Hospital, Boston, MA Department of Neurology and Neurosurgery S L A H, The Children s Hospital at Westmead, University of Sydney, Australia Department of Neurology and Oncology J O B, John Hopkins Medical Institute, Baltimore, MD University Department of Medical Genetics D G E, St Mary s Hospital, Manchester, UK Department of Neurology R E F, Guy s and St Thomas NHS Foundation Trust and Institute of Psychiatry, King s College London, UK Department of Otolaryngology T A H and Audiology C H, Massachusetts Eye and Ear Infirmary and Harvard Medical School T A H, Boston, MA
Neurology 81:S25-32. 2013..Although hearing loss and facial weakness have been identified as important functional outcomes for patients with NF2, there is a lack of consensus regarding appropriate endpoints in clinical trials...
- Twenty years of audiology in a patient with Norrie diseaseChris Halpin
Department of Audiology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 243 Charles Street, Boston, MA 02114, United States
Int J Pediatr Otorhinolaryngol 72:1705-10. 2008..Affected individuals are born blind and develop progressive sensory loss with onset in adolescence. This disease is X-linked and has been associated with mutations of the NDP gene (Xp11.4)...
- Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patientsScott R Plotkin
Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston 02114, USA
Otol Neurotol 33:1046-52. 2012..The aim of this study was to report extended follow-up in a larger cohort of similarly treated patients...
- Hearing improvement after bevacizumab in patients with neurofibromatosis type 2Scott R Plotkin
Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA
N Engl J Med 361:358-67. 2009..There is no medical treatment for such tumors...
- Using audiometric thresholds and word recognition in a treatment studyChris Halpin
Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts 02114, USA
Otol Neurotol 27:110-6. 2006..Second, to examine the outcomes when using two different types of criteria for significant change in a subject's word recognition score...
- Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapyScott R Plotkin
Department of Neurology, Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
Nat Clin Pract Oncol 5:487-91. 2008..A 48-year-old man presented to a neurologist with complaints of bilateral hearing loss and tinnitus. The patient was a member of a large family affected by neurofibromatosis type 2 and first noted hearing loss 10 years before presentation...